interleukin-2 + anti-interleukin-2 monoclonal antibody

Interleukin-2 + anti-interleukin-2 monoclonal antibody is an experimental **cytokine-antibody immunotherapy** consisting of recombinant interleukin-2 complexed with a neutralizing anti-IL-2 monoclonal antibody, most commonly the JES6-1 clone in the cited preclinical work. The complex is designed to alter IL-2 biodistribution and receptor engagement so as to preferentially expand **CD4+CD25+Foxp3+ regulatory T cells** in vivo through the high-affinity interleukin-2 receptor, while limiting broader activation of other immune cell populations. In the provided literature context, this agent has been evaluated in preclinical models rather than as a named clinical-stage commercial drug, including apolipoprotein E-deficient mouse studies showing Treg expansion in spleen, lymph nodes, and liver and reduced atherosclerotic lesion development and progression. It should be regarded as a research-use biologic combination platform rather than a defined marketed pharmaceutical product.

Other names

IL-2 + anti-IL-2 monoclonal antibodyIL-2/anti-IL-2 monoclonal antibody complexinterleukin-2/anti-interleukin-2 monoclonal antibody complexIL-2/anti-IL-2 mAb complex